Physician profile
Thomas Pinder
NPI 1922093962
$2,473.46
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $352 · 2021: $526 · 2022: $264 · 2023: $321 · 2024: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $355.21 | 2019-2023 | Amvuttra |
| Abbott Laboratories | $275.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $261.81 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $253.03 | 2019-2024 | |
| Gilead Sciences, INC. | $218.63 | 2019 | |
| Novo Nordisk INC | $149.92 | 2020-2023 | Ozempic, Rybelsus |
| Amgen INC. | $144.81 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $118.10 | 2019-2021 | |
| Pfizer INC. | $117.03 | 2019-2024 | |
| Cardiva Medical, INC. | $83.81 | 2021-2024 | Cardiva Vascade 6/7f Vcs |
| E.R. Squibb & Sons, L.L.C. | $81.24 | 2019-2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.90 | 2019-2020 | |
| Boston Scientific Corporation | $53.04 | 2019-2023 | Bodyguardian |
| Arbor Pharmaceuticals, INC. | $49.55 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $23.03 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.33 | 2019 | |
| Scpharmaceuticals INC. | $20.75 | 2023 | |
| Abiomed | $18.66 | 2023 | Impella |
| Philips North America LLC | $17.47 | 2024 | (Ck4) Mcot |
| Astrazeneca Pharmaceuticals Lp | $16.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.